Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
CONCLUSIONS: Liposome-paclitaxel and carboplatin concurrent with radiotherapy is a safe and effective modality for locally advanced ESCC. Further clinical investigation are warranted to evaluate the efficacy of this regimen.PMID:33958272 | DOI:10.1016/j.canrad.2021.01.008 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - May 7, 2021 Category: Cancer & Oncology Authors: J Zeng X Cui L Cheng Y Chen X Du L Sheng Source Type: research

Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
CONCLUSIONS: Liposome-paclitaxel and carboplatin concurrent with radiotherapy is a safe and effective modality for locally advanced ESCC. Further clinical investigation are warranted to evaluate the efficacy of this regimen.PMID:33958272 | DOI:10.1016/j.canrad.2021.01.008 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - May 7, 2021 Category: Cancer & Oncology Authors: J Zeng X Cui L Cheng Y Chen X Du L Sheng Source Type: research

Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
CONCLUSIONS: Liposome-paclitaxel and carboplatin concurrent with radiotherapy is a safe and effective modality for locally advanced ESCC. Further clinical investigation are warranted to evaluate the efficacy of this regimen.PMID:33958272 | DOI:10.1016/j.canrad.2021.01.008 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - May 7, 2021 Category: Cancer & Oncology Authors: J Zeng X Cui L Cheng Y Chen X Du L Sheng Source Type: research

Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
CONCLUSIONS: Liposome-paclitaxel and carboplatin concurrent with radiotherapy is a safe and effective modality for locally advanced ESCC. Further clinical investigation are warranted to evaluate the efficacy of this regimen.PMID:33958272 | DOI:10.1016/j.canrad.2021.01.008 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - May 7, 2021 Category: Cancer & Oncology Authors: J Zeng X Cui L Cheng Y Chen X Du L Sheng Source Type: research

Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
CONCLUSIONS: Liposome-paclitaxel and carboplatin concurrent with radiotherapy is a safe and effective modality for locally advanced ESCC. Further clinical investigation are warranted to evaluate the efficacy of this regimen.PMID:33958272 | DOI:10.1016/j.canrad.2021.01.008 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - May 7, 2021 Category: Cancer & Oncology Authors: J Zeng X Cui L Cheng Y Chen X Du L Sheng Source Type: research

Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
CONCLUSIONS: Liposome-paclitaxel and carboplatin concurrent with radiotherapy is a safe and effective modality for locally advanced ESCC. Further clinical investigation are warranted to evaluate the efficacy of this regimen.PMID:33958272 | DOI:10.1016/j.canrad.2021.01.008 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - May 7, 2021 Category: Cancer & Oncology Authors: J Zeng X Cui L Cheng Y Chen X Du L Sheng Source Type: research

Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
CONCLUSIONS: Liposome-paclitaxel and carboplatin concurrent with radiotherapy is a safe and effective modality for locally advanced ESCC. Further clinical investigation are warranted to evaluate the efficacy of this regimen.PMID:33958272 | DOI:10.1016/j.canrad.2021.01.008 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - May 7, 2021 Category: Cancer & Oncology Authors: J Zeng X Cui L Cheng Y Chen X Du L Sheng Source Type: research

Radiotherapy for patients with early-stage glottic squamous cell carcinoma of the larynx: Interest of hypofractionation?
Cancer Radiother. 2021 Apr 27:S1278-3218(21)00056-1. doi: 10.1016/j.canrad.2021.04.004. Online ahead of print.ABSTRACTHypofractionated radiotherapy of early-stage squamous cell carcinoma of the glottic larynx is a promising treatment option. This can be divided into radiotherapy with moderate hypofractionation (up to 2.5Gy per fraction), more intense hypofractionation (between 2.5 and 4.5Gy per fraction) and stereotactic radiotherapy (above 4.5Gy per fraction). Most studies evaluating moderate hypofractionation show a local control rate between 85 and 95%. Acute laryngeal toxicity is superior to conventional treatment, but...
Source: Cancer Radiotherapie - May 1, 2021 Category: Cancer & Oncology Authors: M Tonneau R Matta S Lals X Mirabel F Crop T Lacornerie D Pasquier A Escande X Liem Source Type: research

Radiotherapy for patients with early-stage glottic squamous cell carcinoma of the larynx: Interest of hypofractionation?
Cancer Radiother. 2021 Apr 27:S1278-3218(21)00056-1. doi: 10.1016/j.canrad.2021.04.004. Online ahead of print.ABSTRACTHypofractionated radiotherapy of early-stage squamous cell carcinoma of the glottic larynx is a promising treatment option. This can be divided into radiotherapy with moderate hypofractionation (up to 2.5Gy per fraction), more intense hypofractionation (between 2.5 and 4.5Gy per fraction) and stereotactic radiotherapy (above 4.5Gy per fraction). Most studies evaluating moderate hypofractionation show a local control rate between 85 and 95%. Acute laryngeal toxicity is superior to conventional treatment, but...
Source: Cancer Radiotherapie - May 1, 2021 Category: Cancer & Oncology Authors: M Tonneau R Matta S Lals X Mirabel F Crop T Lacornerie D Pasquier A Escande X Liem Source Type: research

Radiotherapy for patients with early-stage glottic squamous cell carcinoma of the larynx: Interest of hypofractionation?
Cancer Radiother. 2021 Apr 27:S1278-3218(21)00056-1. doi: 10.1016/j.canrad.2021.04.004. Online ahead of print.ABSTRACTHypofractionated radiotherapy of early-stage squamous cell carcinoma of the glottic larynx is a promising treatment option. This can be divided into radiotherapy with moderate hypofractionation (up to 2.5Gy per fraction), more intense hypofractionation (between 2.5 and 4.5Gy per fraction) and stereotactic radiotherapy (above 4.5Gy per fraction). Most studies evaluating moderate hypofractionation show a local control rate between 85 and 95%. Acute laryngeal toxicity is superior to conventional treatment, but...
Source: Cancer Radiotherapie - May 1, 2021 Category: Cancer & Oncology Authors: M Tonneau R Matta S Lals X Mirabel F Crop T Lacornerie D Pasquier A Escande X Liem Source Type: research

Radiotherapy for patients with early-stage glottic squamous cell carcinoma of the larynx: Interest of hypofractionation?
Cancer Radiother. 2021 Apr 27:S1278-3218(21)00056-1. doi: 10.1016/j.canrad.2021.04.004. Online ahead of print.ABSTRACTHypofractionated radiotherapy of early-stage squamous cell carcinoma of the glottic larynx is a promising treatment option. This can be divided into radiotherapy with moderate hypofractionation (up to 2.5Gy per fraction), more intense hypofractionation (between 2.5 and 4.5Gy per fraction) and stereotactic radiotherapy (above 4.5Gy per fraction). Most studies evaluating moderate hypofractionation show a local control rate between 85 and 95%. Acute laryngeal toxicity is superior to conventional treatment, but...
Source: Cancer Radiotherapie - May 1, 2021 Category: Cancer & Oncology Authors: M Tonneau R Matta S Lals X Mirabel F Crop T Lacornerie D Pasquier A Escande X Liem Source Type: research

Radiotherapy for patients with early-stage glottic squamous cell carcinoma of the larynx: Interest of hypofractionation?
Cancer Radiother. 2021 Apr 27:S1278-3218(21)00056-1. doi: 10.1016/j.canrad.2021.04.004. Online ahead of print.ABSTRACTHypofractionated radiotherapy of early-stage squamous cell carcinoma of the glottic larynx is a promising treatment option. This can be divided into radiotherapy with moderate hypofractionation (up to 2.5Gy per fraction), more intense hypofractionation (between 2.5 and 4.5Gy per fraction) and stereotactic radiotherapy (above 4.5Gy per fraction). Most studies evaluating moderate hypofractionation show a local control rate between 85 and 95%. Acute laryngeal toxicity is superior to conventional treatment, but...
Source: Cancer Radiotherapie - May 1, 2021 Category: Cancer & Oncology Authors: M Tonneau R Matta S Lals X Mirabel F Crop T Lacornerie D Pasquier A Escande X Liem Source Type: research

Late vascular complications after cranial radiotherapy: A report of two illustrative cases
We present two cases of late neurological complications after CRT and briefly discuss its diagnosis and their shared pathophysiological aspects. The first case is a patient with cognitive impairment associated to mineralizing microangiopathy ten years after CRT for nasopharyngeal carcinoma and the second one is a woman with Stroke-like Migraine Attacks after Radiation Therapy (SMART) syndrome two years after CRT for anaplastic meningioma. Nowadays, higher survival rates might cause an increase in appearance of late neurological complications after CTR. These reported cases show that late complications can mimic a wide vari...
Source: Cancer Radiotherapie - April 27, 2021 Category: Cancer & Oncology Authors: J Madera A S ánchez-Soblechero P Navarrete Solano U Corro Verde E Marco de Lucas M Pacheco Baldor P J Prada J Pascual Source Type: research

Low dose radiotherapy for COVID-19 pneumopathy: Biological rationale and literature review
This article explains biological rationale of low-dose radiotherapy, and reports already published or ongoing studies on low-dose radiotherapy for SARS-CoV-2 pneumonia.PMID:33903009 | PMC:PMC8040522 | DOI:10.1016/j.canrad.2021.03.005 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - April 27, 2021 Category: Cancer & Oncology Authors: C Miran É Bonnet B Allignet S Clippe M El Hedi Zouai M Bosset B Fleury J-B Guy Source Type: research

Late vascular complications after cranial radiotherapy: A report of two illustrative cases
We present two cases of late neurological complications after CRT and briefly discuss its diagnosis and their shared pathophysiological aspects. The first case is a patient with cognitive impairment associated to mineralizing microangiopathy ten years after CRT for nasopharyngeal carcinoma and the second one is a woman with Stroke-like Migraine Attacks after Radiation Therapy (SMART) syndrome two years after CRT for anaplastic meningioma. Nowadays, higher survival rates might cause an increase in appearance of late neurological complications after CTR. These reported cases show that late complications can mimic a wide vari...
Source: Cancer Radiotherapie - April 27, 2021 Category: Cancer & Oncology Authors: J Madera A S ánchez-Soblechero P Navarrete Solano U Corro Verde E Marco de Lucas M Pacheco Baldor P J Prada J Pascual Source Type: research

Low dose radiotherapy for COVID-19 pneumopathy: Biological rationale and literature review
This article explains biological rationale of low-dose radiotherapy, and reports already published or ongoing studies on low-dose radiotherapy for SARS-CoV-2 pneumonia.PMID:33903009 | PMC:PMC8040522 | DOI:10.1016/j.canrad.2021.03.005 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - April 27, 2021 Category: Cancer & Oncology Authors: C Miran É Bonnet B Allignet S Clippe M El Hedi Zouai M Bosset B Fleury J-B Guy Source Type: research

Late vascular complications after cranial radiotherapy: A report of two illustrative cases
We present two cases of late neurological complications after CRT and briefly discuss its diagnosis and their shared pathophysiological aspects. The first case is a patient with cognitive impairment associated to mineralizing microangiopathy ten years after CRT for nasopharyngeal carcinoma and the second one is a woman with Stroke-like Migraine Attacks after Radiation Therapy (SMART) syndrome two years after CRT for anaplastic meningioma. Nowadays, higher survival rates might cause an increase in appearance of late neurological complications after CTR. These reported cases show that late complications can mimic a wide vari...
Source: Cancer Radiotherapie - April 27, 2021 Category: Cancer & Oncology Authors: J Madera A S ánchez-Soblechero P Navarrete Solano U Corro Verde E Marco de Lucas M Pacheco Baldor P J Prada J Pascual Source Type: research

Low dose radiotherapy for COVID-19 pneumopathy: Biological rationale and literature review
This article explains biological rationale of low-dose radiotherapy, and reports already published or ongoing studies on low-dose radiotherapy for SARS-CoV-2 pneumonia.PMID:33903009 | PMC:PMC8040522 | DOI:10.1016/j.canrad.2021.03.005 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - April 27, 2021 Category: Cancer & Oncology Authors: C Miran É Bonnet B Allignet S Clippe M El Hedi Zouai M Bosset B Fleury J-B Guy Source Type: research

Late vascular complications after cranial radiotherapy: A report of two illustrative cases
We present two cases of late neurological complications after CRT and briefly discuss its diagnosis and their shared pathophysiological aspects. The first case is a patient with cognitive impairment associated to mineralizing microangiopathy ten years after CRT for nasopharyngeal carcinoma and the second one is a woman with Stroke-like Migraine Attacks after Radiation Therapy (SMART) syndrome two years after CRT for anaplastic meningioma. Nowadays, higher survival rates might cause an increase in appearance of late neurological complications after CTR. These reported cases show that late complications can mimic a wide vari...
Source: Cancer Radiotherapie - April 27, 2021 Category: Cancer & Oncology Authors: J Madera A S ánchez-Soblechero P Navarrete Solano U Corro Verde E Marco de Lucas M Pacheco Baldor P J Prada J Pascual Source Type: research

Low dose radiotherapy for COVID-19 pneumopathy: Biological rationale and literature review
This article explains biological rationale of low-dose radiotherapy, and reports already published or ongoing studies on low-dose radiotherapy for SARS-CoV-2 pneumonia.PMID:33903009 | DOI:10.1016/j.canrad.2021.03.005 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - April 27, 2021 Category: Cancer & Oncology Authors: C Miran É Bonnet B Allignet S Clippe M El Hedi Zouai M Bosset B Fleury J-B Guy Source Type: research

Radiotherapy is effective in the management of rare penile metastases: Two case reports
We report two cases of penile metastasis, from primitive prostatic adenocarcinoma and primitive urothelial carcinoma, effectively managed with radiation treatment at our institution. A three-dimensional conformal radiation therapy with 42Gy to the planning target volume in 14 fractions was delivered. Radiation treatment was safely delivered, with low toxicity profile and achieved adequate symptoms control without compromising genitourinary functions. Radiation therapy should be considered in management of rare penile metastases.PMID:33896682 | DOI:10.1016/j.canrad.2021.03.004 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - April 26, 2021 Category: Cancer & Oncology Authors: B Detti A Sardaro V Maragna M Mariotti G Stocchi M Roghi M A Teriaca G Francolini B Guerrieri L Livi Source Type: research

The 30th anniversary of SFRO, the French society of oncological radiotherapy
Cancer Radiother. 2021 Apr 16:S1278-3218(21)00050-0. doi: 10.1016/j.canrad.2021.03.003. Online ahead of print.ABSTRACTThe French society of oncological radiotherapy (Société française de radiothérapie oncologique, SFRO) was created in 1990. On the occasion of its thirtieth annual congress, in October 2019, a session was devoted to it, with the objective of exposing its functioning, its actions and its productions during these three decades during which radiotherapy and oncology have undergone unprecedented transformations. We propose in this article to outline the content of this session.PMID:33...
Source: Cancer Radiotherapie - April 20, 2021 Category: Cancer & Oncology Authors: J-J Mazeron F Mornex J-M Cosset F Eschw ège Source Type: research

The 30th anniversary of SFRO, the French society of oncological radiotherapy
Cancer Radiother. 2021 Apr 16:S1278-3218(21)00050-0. doi: 10.1016/j.canrad.2021.03.003. Online ahead of print.ABSTRACTThe French society of oncological radiotherapy (Société française de radiothérapie oncologique, SFRO) was created in 1990. On the occasion of its thirtieth annual congress, in October 2019, a session was devoted to it, with the objective of exposing its functioning, its actions and its productions during these three decades during which radiotherapy and oncology have undergone unprecedented transformations. We propose in this article to outline the content of this session.PMID:33...
Source: Cancer Radiotherapie - April 20, 2021 Category: Cancer & Oncology Authors: J-J Mazeron F Mornex J-M Cosset F Eschw ège Source Type: research

The 30th anniversary of SFRO, the French society of oncological radiotherapy
Cancer Radiother. 2021 Apr 16:S1278-3218(21)00050-0. doi: 10.1016/j.canrad.2021.03.003. Online ahead of print.ABSTRACTThe French society of oncological radiotherapy (Société française de radiothérapie oncologique, SFRO) was created in 1990. On the occasion of its thirtieth annual congress, in October 2019, a session was devoted to it, with the objective of exposing its functioning, its actions and its productions during these three decades during which radiotherapy and oncology have undergone unprecedented transformations. We propose in this article to outline the content of this session.PMID:33...
Source: Cancer Radiotherapie - April 20, 2021 Category: Cancer & Oncology Authors: J-J Mazeron F Mornex J-M Cosset F Eschw ège Source Type: research

The 30th anniversary of SFRO, the French society of oncological radiotherapy
Cancer Radiother. 2021 Apr 16:S1278-3218(21)00050-0. doi: 10.1016/j.canrad.2021.03.003. Online ahead of print.ABSTRACTThe French society of oncological radiotherapy (Société française de radiothérapie oncologique, SFRO) was created in 1990. On the occasion of its thirtieth annual congress, in October 2019, a session was devoted to it, with the objective of exposing its functioning, its actions and its productions during these three decades during which radiotherapy and oncology have undergone unprecedented transformations. We propose in this article to outline the content of this session.PMID:33...
Source: Cancer Radiotherapie - April 20, 2021 Category: Cancer & Oncology Authors: J-J Mazeron F Mornex J-M Cosset F Eschw ège Source Type: research

The 30th anniversary of SFRO, the French society of oncological radiotherapy
Cancer Radiother. 2021 Apr 16:S1278-3218(21)00050-0. doi: 10.1016/j.canrad.2021.03.003. Online ahead of print.ABSTRACTThe French society of oncological radiotherapy (Société française de radiothérapie oncologique, SFRO) was created in 1990. On the occasion of its thirtieth annual congress, in October 2019, a session was devoted to it, with the objective of exposing its functioning, its actions and its productions during these three decades during which radiotherapy and oncology have undergone unprecedented transformations. We propose in this article to outline the content of this session.PMID:33...
Source: Cancer Radiotherapie - April 20, 2021 Category: Cancer & Oncology Authors: J-J Mazeron F Mornex J-M Cosset F Eschw ège Source Type: research

The 30th anniversary of SFRO, the French society of oncological radiotherapy
Cancer Radiother. 2021 Apr 16:S1278-3218(21)00050-0. doi: 10.1016/j.canrad.2021.03.003. Online ahead of print.ABSTRACTThe French society of oncological radiotherapy (Société française de radiothérapie oncologique, SFRO) was created in 1990. On the occasion of its thirtieth annual congress, in October 2019, a session was devoted to it, with the objective of exposing its functioning, its actions and its productions during these three decades during which radiotherapy and oncology have undergone unprecedented transformations. We propose in this article to outline the content of this session.PMID:33...
Source: Cancer Radiotherapie - April 20, 2021 Category: Cancer & Oncology Authors: J-J Mazeron F Mornex J-M Cosset F Eschw ège Source Type: research

Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases
The objective was to retrospectively evaluate the influence of the time-lapse between immunotherapy and stereotactic radiotherapy on toxicity.PATIENTS AND METHODS: From 2016 to 2019, 59 patients treated with SRT for 103 brain metastases of NSCLC (60%) and melanoma (40%) in combination with concomitant immunotherapy (≤30 days) were included. The prescribed dose was 20Gy/1f or 33Gy/3f at the isocentre and 14Gy or 23.1Gy (70%) respectively at the PTV envelope (PTV=GTV+2mm). The mean tumour diameter was 14mm (4-52mm). The immunotherapies used were anti-PD1 and anti-PDL1. The 103 metastases were classified into 3 groups acco...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: C Cabanie J Biau X Durando S Mansard I Molnar V Chassin P Verrelle T Khalil M Lapeyre G Dupic Source Type: research

Predictive factors for mandibular osteoradionecrosis after irradiation of head and neck cancers
Cancer Radiother. 2021 Apr 6:S1278-3218(21)00049-4. doi: 10.1016/j.canrad.2021.03.002. Online ahead of print.ABSTRACTThe identification of the different risk factors for mandibular osteoradionecrosis (ORN) must be done before and after the management of patients with head and neck cancer. Various clinical criteria for this severe radiation-induced complication are related to the patient (intrinsic radiosensitivity, malnutrition associated with thin weight loss, active smoking intoxication, microcapillary involvement, precarious oral status, hyposalivation) and/or related to the disease (oral cavity, large tumor size, tumor...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: F Dutheil F Guillemin J Biau N Pham-Dang N Saroul P Clav ère M Lapeyre Source Type: research

Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases
The objective was to retrospectively evaluate the influence of the time-lapse between immunotherapy and stereotactic radiotherapy on toxicity.PATIENTS AND METHODS: From 2016 to 2019, 59 patients treated with SRT for 103 brain metastases of NSCLC (60%) and melanoma (40%) in combination with concomitant immunotherapy (≤30 days) were included. The prescribed dose was 20Gy/1f or 33Gy/3f at the isocentre and 14Gy or 23.1Gy (70%) respectively at the PTV envelope (PTV=GTV+2mm). The mean tumour diameter was 14mm (4-52mm). The immunotherapies used were anti-PD1 and anti-PDL1. The 103 metastases were classified into 3 groups acco...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: C Cabanie J Biau X Durando S Mansard I Molnar V Chassin P Verrelle T Khalil M Lapeyre G Dupic Source Type: research

Predictive factors for mandibular osteoradionecrosis after irradiation of head and neck cancers
Cancer Radiother. 2021 Apr 6:S1278-3218(21)00049-4. doi: 10.1016/j.canrad.2021.03.002. Online ahead of print.ABSTRACTThe identification of the different risk factors for mandibular osteoradionecrosis (ORN) must be done before and after the management of patients with head and neck cancer. Various clinical criteria for this severe radiation-induced complication are related to the patient (intrinsic radiosensitivity, malnutrition associated with thin weight loss, active smoking intoxication, microcapillary involvement, precarious oral status, hyposalivation) and/or related to the disease (oral cavity, large tumor size, tumor...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: F Dutheil F Guillemin J Biau N Pham-Dang N Saroul P Clav ère M Lapeyre Source Type: research

Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases
The objective was to retrospectively evaluate the influence of the time-lapse between immunotherapy and stereotactic radiotherapy on toxicity.PATIENTS AND METHODS: From 2016 to 2019, 59 patients treated with SRT for 103 brain metastases of NSCLC (60%) and melanoma (40%) in combination with concomitant immunotherapy (≤30 days) were included. The prescribed dose was 20Gy/1f or 33Gy/3f at the isocentre and 14Gy or 23.1Gy (70%) respectively at the PTV envelope (PTV=GTV+2mm). The mean tumour diameter was 14mm (4-52mm). The immunotherapies used were anti-PD1 and anti-PDL1. The 103 metastases were classified into 3 groups acco...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: C Cabanie J Biau X Durando S Mansard I Molnar V Chassin P Verrelle T Khalil M Lapeyre G Dupic Source Type: research

Predictive factors for mandibular osteoradionecrosis after irradiation of head and neck cancers
Cancer Radiother. 2021 Apr 6:S1278-3218(21)00049-4. doi: 10.1016/j.canrad.2021.03.002. Online ahead of print.ABSTRACTThe identification of the different risk factors for mandibular osteoradionecrosis (ORN) must be done before and after the management of patients with head and neck cancer. Various clinical criteria for this severe radiation-induced complication are related to the patient (intrinsic radiosensitivity, malnutrition associated with thin weight loss, active smoking intoxication, microcapillary involvement, precarious oral status, hyposalivation) and/or related to the disease (oral cavity, large tumor size, tumor...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: F Dutheil F Guillemin J Biau N Pham-Dang N Saroul P Clav ère M Lapeyre Source Type: research

Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases
The objective was to retrospectively evaluate the influence of the time-lapse between immunotherapy and stereotactic radiotherapy on toxicity.PATIENTS AND METHODS: From 2016 to 2019, 59 patients treated with SRT for 103 brain metastases of NSCLC (60%) and melanoma (40%) in combination with concomitant immunotherapy (≤30 days) were included. The prescribed dose was 20Gy/1f or 33Gy/3f at the isocentre and 14Gy or 23.1Gy (70%) respectively at the PTV envelope (PTV=GTV+2mm). The mean tumour diameter was 14mm (4-52mm). The immunotherapies used were anti-PD1 and anti-PDL1. The 103 metastases were classified into 3 groups acco...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: C Cabanie J Biau X Durando S Mansard I Molnar V Chassin P Verrelle T Khalil M Lapeyre G Dupic Source Type: research

Predictive factors for mandibular osteoradionecrosis after irradiation of head and neck cancers
Cancer Radiother. 2021 Apr 6:S1278-3218(21)00049-4. doi: 10.1016/j.canrad.2021.03.002. Online ahead of print.ABSTRACTThe identification of the different risk factors for mandibular osteoradionecrosis (ORN) must be done before and after the management of patients with head and neck cancer. Various clinical criteria for this severe radiation-induced complication are related to the patient (intrinsic radiosensitivity, malnutrition associated with thin weight loss, active smoking intoxication, microcapillary involvement, precarious oral status, hyposalivation) and/or related to the disease (oral cavity, large tumor size, tumor...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: F Dutheil F Guillemin J Biau N Pham-Dang N Saroul P Clav ère M Lapeyre Source Type: research

Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases
The objective was to retrospectively evaluate the influence of the time-lapse between immunotherapy and stereotactic radiotherapy on toxicity.PATIENTS AND METHODS: From 2016 to 2019, 59 patients treated with SRT for 103 brain metastases of NSCLC (60%) and melanoma (40%) in combination with concomitant immunotherapy (≤30 days) were included. The prescribed dose was 20Gy/1f or 33Gy/3f at the isocentre and 14Gy or 23.1Gy (70%) respectively at the PTV envelope (PTV=GTV+2mm). The mean tumour diameter was 14mm (4-52mm). The immunotherapies used were anti-PD1 and anti-PDL1. The 103 metastases were classified into 3 groups acco...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: C Cabanie J Biau X Durando S Mansard I Molnar V Chassin P Verrelle T Khalil M Lapeyre G Dupic Source Type: research

Predictive factors for mandibular osteoradionecrosis after irradiation of head and neck cancers
Cancer Radiother. 2021 Apr 6:S1278-3218(21)00049-4. doi: 10.1016/j.canrad.2021.03.002. Online ahead of print.ABSTRACTThe identification of the different risk factors for mandibular osteoradionecrosis (ORN) must be done before and after the management of patients with head and neck cancer. Various clinical criteria for this severe radiation-induced complication are related to the patient (intrinsic radiosensitivity, malnutrition associated with thin weight loss, active smoking intoxication, microcapillary involvement, precarious oral status, hyposalivation) and/or related to the disease (oral cavity, large tumor size, tumor...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: F Dutheil F Guillemin J Biau N Pham-Dang N Saroul P Clav ère M Lapeyre Source Type: research

Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases
The objective was to retrospectively evaluate the influence of the time-lapse between immunotherapy and stereotactic radiotherapy on toxicity.PATIENTS AND METHODS: From 2016 to 2019, 59 patients treated with SRT for 103 brain metastases of NSCLC (60%) and melanoma (40%) in combination with concomitant immunotherapy (≤30 days) were included. The prescribed dose was 20Gy/1f or 33Gy/3f at the isocentre and 14Gy or 23.1Gy (70%) respectively at the PTV envelope (PTV=GTV+2mm). The mean tumour diameter was 14mm (4-52mm). The immunotherapies used were anti-PD1 and anti-PDL1. The 103 metastases were classified into 3 groups acco...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: C Cabanie J Biau X Durando S Mansard I Molnar V Chassin P Verrelle T Khalil M Lapeyre G Dupic Source Type: research

Predictive factors for mandibular osteoradionecrosis after irradiation of head and neck cancers
Cancer Radiother. 2021 Apr 6:S1278-3218(21)00049-4. doi: 10.1016/j.canrad.2021.03.002. Online ahead of print.ABSTRACTThe identification of the different risk factors for mandibular osteoradionecrosis (ORN) must be done before and after the management of patients with head and neck cancer. Various clinical criteria for this severe radiation-induced complication are related to the patient (intrinsic radiosensitivity, malnutrition associated with thin weight loss, active smoking intoxication, microcapillary involvement, precarious oral status, hyposalivation) and/or related to the disease (oral cavity, large tumor size, tumor...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: F Dutheil F Guillemin J Biau N Pham-Dang N Saroul P Clav ère M Lapeyre Source Type: research

Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases
The objective was to retrospectively evaluate the influence of the time-lapse between immunotherapy and stereotactic radiotherapy on toxicity.PATIENTS AND METHODS: From 2016 to 2019, 59 patients treated with SRT for 103 brain metastases of NSCLC (60%) and melanoma (40%) in combination with concomitant immunotherapy (≤30 days) were included. The prescribed dose was 20Gy/1f or 33Gy/3f at the isocentre and 14Gy or 23.1Gy (70%) respectively at the PTV envelope (PTV=GTV+2mm). The mean tumour diameter was 14mm (4-52mm). The immunotherapies used were anti-PD1 and anti-PDL1. The 103 metastases were classified into 3 groups acco...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: C Cabanie J Biau X Durando S Mansard I Molnar V Chassin P Verrelle T Khalil M Lapeyre G Dupic Source Type: research

Predictive factors for mandibular osteoradionecrosis after irradiation of head and neck cancers
Cancer Radiother. 2021 Apr 6:S1278-3218(21)00049-4. doi: 10.1016/j.canrad.2021.03.002. Online ahead of print.ABSTRACTThe identification of the different risk factors for mandibular osteoradionecrosis (ORN) must be done before and after the management of patients with head and neck cancer. Various clinical criteria for this severe radiation-induced complication are related to the patient (intrinsic radiosensitivity, malnutrition associated with thin weight loss, active smoking intoxication, microcapillary involvement, precarious oral status, hyposalivation) and/or related to the disease (oral cavity, large tumor size, tumor...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: F Dutheil F Guillemin J Biau N Pham-Dang N Saroul P Clav ère M Lapeyre Source Type: research

Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases
The objective was to retrospectively evaluate the influence of the time-lapse between immunotherapy and stereotactic radiotherapy on toxicity.PATIENTS AND METHODS: From 2016 to 2019, 59 patients treated with SRT for 103 brain metastases of NSCLC (60%) and melanoma (40%) in combination with concomitant immunotherapy (≤30 days) were included. The prescribed dose was 20Gy/1f or 33Gy/3f at the isocentre and 14Gy or 23.1Gy (70%) respectively at the PTV envelope (PTV=GTV+2mm). The mean tumour diameter was 14mm (4-52mm). The immunotherapies used were anti-PD1 and anti-PDL1. The 103 metastases were classified into 3 groups acco...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: C Cabanie J Biau X Durando S Mansard I Molnar V Chassin P Verrelle T Khalil M Lapeyre G Dupic Source Type: research

Predictive factors for mandibular osteoradionecrosis after irradiation of head and neck cancers
Cancer Radiother. 2021 Apr 6:S1278-3218(21)00049-4. doi: 10.1016/j.canrad.2021.03.002. Online ahead of print.ABSTRACTThe identification of the different risk factors for mandibular osteoradionecrosis (ORN) must be done before and after the management of patients with head and neck cancer. Various clinical criteria for this severe radiation-induced complication are related to the patient (intrinsic radiosensitivity, malnutrition associated with thin weight loss, active smoking intoxication, microcapillary involvement, precarious oral status, hyposalivation) and/or related to the disease (oral cavity, large tumor size, tumor...
Source: Cancer Radiotherapie - April 10, 2021 Category: Cancer & Oncology Authors: F Dutheil F Guillemin J Biau N Pham-Dang N Saroul P Clav ère M Lapeyre Source Type: research

The effect of patient positioning (prone or supine) on the dose received by small bowel in pelvic radiotherapy in rectal cancer patients
CONCLUSION: Supine position could be accepted for the patients undergoing preoperative rectal cancer chemo-radiation.PMID:33812778 | DOI:10.1016/j.canrad.2020.04.013 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - April 4, 2021 Category: Cancer & Oncology Authors: E Esmati M Barzegartahamtan A Maddah A Alikhassi V Vaezzadeh R Mohammadpour Source Type: research

The effect of patient positioning (prone or supine) on the dose received by small bowel in pelvic radiotherapy in rectal cancer patients
CONCLUSION: Supine position could be accepted for the patients undergoing preoperative rectal cancer chemo-radiation.PMID:33812778 | DOI:10.1016/j.canrad.2020.04.013 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - April 4, 2021 Category: Cancer & Oncology Authors: E Esmati M Barzegartahamtan A Maddah A Alikhassi V Vaezzadeh R Mohammadpour Source Type: research

The effect of patient positioning (prone or supine) on the dose received by small bowel in pelvic radiotherapy in rectal cancer patients
CONCLUSION: Supine position could be accepted for the patients undergoing preoperative rectal cancer chemo-radiation.PMID:33812778 | DOI:10.1016/j.canrad.2020.04.013 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - April 4, 2021 Category: Cancer & Oncology Authors: E Esmati M Barzegartahamtan A Maddah A Alikhassi V Vaezzadeh R Mohammadpour Source Type: research

The effect of patient positioning (prone or supine) on the dose received by small bowel in pelvic radiotherapy in rectal cancer patients
CONCLUSION: Supine position could be accepted for the patients undergoing preoperative rectal cancer chemo-radiation.PMID:33812778 | DOI:10.1016/j.canrad.2020.04.013 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - April 4, 2021 Category: Cancer & Oncology Authors: E Esmati M Barzegartahamtan A Maddah A Alikhassi V Vaezzadeh R Mohammadpour Source Type: research

Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity
CONCLUSION: The concurrent use of radiotherapy, pertuzumab and trastuzumab is feasible with good tolerance. Larger prospective data with longer follow-up is needed to confirm these results.PMID:33771453 | DOI:10.1016/j.canrad.2020.06.037 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - March 27, 2021 Category: Cancer & Oncology Authors: S Ben Dhia P Loap D Loirat A Vincent-Salomon K Cao L Escalup A Fourquet Y Kirova Source Type: research

Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity
CONCLUSION: The concurrent use of radiotherapy, pertuzumab and trastuzumab is feasible with good tolerance. Larger prospective data with longer follow-up is needed to confirm these results.PMID:33771453 | DOI:10.1016/j.canrad.2020.06.037 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - March 27, 2021 Category: Cancer & Oncology Authors: S Ben Dhia P Loap D Loirat A Vincent-Salomon K Cao L Escalup A Fourquet Y Kirova Source Type: research

Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity
CONCLUSION: The concurrent use of radiotherapy, pertuzumab and trastuzumab is feasible with good tolerance. Larger prospective data with longer follow-up is needed to confirm these results.PMID:33771453 | DOI:10.1016/j.canrad.2020.06.037 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - March 27, 2021 Category: Cancer & Oncology Authors: S Ben Dhia P Loap D Loirat A Vincent-Salomon K Cao L Escalup A Fourquet Y Kirova Source Type: research